ClinicalTrials.gg
TerminatedNCT04268199EASEUpdated Oct 28, 2026

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

A Phase 2 interventional study of Bortezomib Injection in Myeloma and Myeloma Multiple, sponsored by AHS Cancer Control Alberta. Terminated at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Primary conditionMultiple MyelomaRegistry: Neoplasms, Plasma CellReclassifiedWhy we changed it
Registry
Neoplasms, Plasma Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. The study's listed conditions name Multiple Myeloma, a narrower term within Neoplasms, Plasma Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AHS Cancer Control Alberta · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Operational limitations
Updated Oct 28, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
146th of 267
39 · median 41
Started
2020
with 3 others
Phase 2
137 of 271
6 open now
Registered
239th of 271
by date

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 146th largest by enrollment of the 267 interventional ones that give a count, is one of 4 that started in 2020, is one of 137 in phase 2, and was the 239th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.

Read the detailed description

Chemotherapy for malignancies is predominantly prescribed and delivered in a tertiary hospital and/or cancer centre setting. However, with modern chemotherapy, with a reduced side effect profile, this paradigm should be challenged. Indeed, the use of methotrexate and other biologics (a form of chemotherapy) in the Rheumatologic setting is commonly delivered effectively and safely in the community.

Taken together, a hospital-based model of chemotherapy delivery may not be warranted in all circumstances. Moreover, the use of this current model invariably discounts the time commitments, needs of patients and caregivers, as well as while not addressing the emerging concerns regarding system capacity, efficiency and effectiveness of safe chemotherapy delivery.

03

Conditions studied

  • Myeloma
  • Myeloma Multiple

Browse trials for

04

In context

Multiple Myeloma Reclassified

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

This study's enrollment of 39 is close to the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

AHS Cancer Control Alberta is the lead sponsor of 187 studies on the registry; 24 are open to participants now.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms, Plasma Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma,
  • Stable clinical status as deemed by responsible investigator,
  • Personally (or caregiver) willing and deemed capable to self-administer with teaching,
  • Previously received more than 4 injections of bortezomib within the hospital and/or cancer centre environment,
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Currently participating in clinical trials that includes the use of bortezomib,
  • History of allergic reactions to bortezomib,
  • History of bleeding attributable to bortezomib,
  • History of greater than or equal to grade 3 side effects attributable to bortezomib,
  • Clinically deemed unlikely to be compliant with therapy by responsible investigator,
  • anticipated to be less than 6 months,
  • Deemed geographically inaccessible to receive care.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Other
    Self Injection of Bortezomib

    Subcutaneous self administration of bortezomib

    Drug: Bortezomib Injection

Interventions

07

What researchers measure

Primary outcomes

  1. Number of patients able to self-administer

    Number of eligible patients availing of self-administration

    Time frame: 2 years from study start

  2. Myeloma response outcomes

    Myeloma outcomes as per International Myeloma Foundation Response (IMWG) Criteria. For the purposes of this trial, best response will be documented.

    Time frame: 2 years from study start

  3. Adverse events great than grade 3

    Adverse event documentation as per CTCAE version 5.0 scales of greater than grade 3

    Time frame: 2 years from study start

  4. Number of patients with missed doses

    Proportion of missed doses

    Time frame: 2 years from study start

  5. Patient Satisfaction and Quality of Life Survey 1

    Patient Satisfaction Surveys - FACIT-TS-PS (Functional Assessment of Chronic Illness Therapy)

    Time frame: 2 years from study start

  6. Patient Satisfaction and Quality of Life Survey 2

    Patient Satisfaction Surveys - CQOLC (Caregiver Quality of Life - Cancer)

    Time frame: 2 years from study start

  7. Patient Satisfaction and Quality of Life Survey 3

    Patient Satisfaction Surveys - EORTC QLQ-MY20 (European Organization of Research and Treatment of Cancer - Quality of Life)

    Time frame: 2 years from study start

08

Study locations

2 sites
  • Arthur J.E. Child Comprehensive Cancer Centre
    Calgary, Alberta T2N 5G2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2020 to primary completion in Aug 2026, 75 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2026 → Aug 2026 and completion Dec 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2020
First posted
Feb 13, 2020
StartActual
May 29, 2020
Primary completionActual
Aug 31, 2026was Dec 2026
CompletionActual
Aug 31, 2026was Dec 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Operational limitations
changed Oct 28, 2026
Primary completion
Dec 2026→Aug 31, 2026 (actual)
Oct 28, 2026
Study completion
Dec 2026→Aug 31, 2026 (actual)
Oct 28, 2026
Enrollment
100 (estimated)→39 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Terminated
    Why stopped Operational limitations
    Primary completion Dec 2026→Aug 31, 2026 (now actual)
    Study completion Dec 2026→Aug 31, 2026 (now actual)
    Enrollment 100 (estimated)→39 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04268199
Responsible party
Sponsor
First posted
Feb 13, 2020
Start date
May 29, 2020
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026
Last update
Oct 28, 2026

Study contacts

Jason Tay, MD
principal investigator · Arthur J.E. Child Comprehensive Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion